Logical Therapeutics closes $16.9M round for NSAID program

After disclosing recently that it had landed the first $10 million of a Series C, Logical Therapeutics today announced that it has closed its $16.9 million round, with SV Life Sciences leading a group that includes Burrill & Company, Novo A/S, and Novitas Capital. The biotech is attempting to create safer NSAID prodrugs. LT-NS001, its lead therapy, is in a Phase IIb/III study comparing the cumulative rate of gastric ulcers versus naproxen in osteoarthritis patients after...

Logical Therapeutics raises cash for mid-stage NSAID trial

Logical Therapeutics has pulled in the first $10 million in a planned $16.9 million round, according to Xconomy, citing documents filed with the Securities and Exchange Commission. The company's president declined comment on the SEC filing, but several weeks ago the Waltham, MA-based developer revealed that it had begun a Phase IIb trial of a new form of naproxen, an NSAID pain therapy known to be very effective but one that has also been linked to a long list of side effects. Finding...